aiqbench analysis

Envisagenics has secured a $2 million National Cancer Institute grant to scale its proprietary AI platform for genomic splicing, which aims to accelerate the discovery of cancer treatments. This funding will directly support the expansion of their machine learning models designed to identify and correct genetic mutations in tumor cells. The initiative represents a significant step toward translating advanced computational biology into clinical applications for oncology.